HIV is a retrovirus that causes acquired immuno-deficiency syndrome (AIDS). This progressive collapse of cellular immune response renders commonly harmless infections and cancers to become severe. They are caused by pathogens such as Candida, M. tuberculosis or latent herpes viruses (e.g. EBV, HCMV). In infected individuals, HIV is present as free particles and in infected immune cells (specifically CD4+ cells). Entry of HIV into cells requires the interaction of the viral envelope protein gp120 with the CD4 glycoprotein and a chemokine receptor on the host cell surface.
Development of a potential vaccine is an important goal to AIDS researchers. Immune correlate analysis of the largest clinical trial so far (RV144 or Thai trial) was performed with the help of JPT’s RepliTope™ Antigen Collection HIV Microarrays. The results showed that the presence of IgG against the V2 loop of gp120 is highly correlated with reduced risk of infection. Other vaccination strategies aim to stimulate specific cytotoxic T-lymphocytes.
Cellular Immune Response Profiling
JPT offers peptide libraries and peptide pools for HIV research and clinical in-vitro assays. We provide knowledgeable support, high quality, flexible and innovative formats combined with expert know-how to bring forward your research project. In addition, we offer GxP Peptides & Pools for immunotherapy and specific clinical applications at attractive pricing.
- Development of immunotherapies & vaccination strategies
- Assessment of vaccine efficacy & immune correlation
- Validating clinical T-cell assays
HIV Ultra PepMixes™
ENV, GAG, NEF and POL peptide pools were designed with focus on high coverage. A proprietary algorithm was used to obtain peptide combinations providing an optimal coverage of sequence variability.
Tailored HIV PepMix™ Peptide Pools
Peptide Pools tailored for your specific needs!
- Vaccine development
- High-throughput T-cell epitope discovery
- Monitoring of cellular immune response
- Clinical trials
We are the experts for peptide synthesis with highest quality optimized for many applications. Our peptide synthesis service has a very high success rate (over 99%) as we optimize the appropriate peptide synthesis method for each peptide.
If you would like to order a quality peptide synthesis using regulated processes, choose JPT!
Humoral Immune Response Profiling
JPT is the technology leader for peptide microarrays. We offer a range of premade catalog microarrays (RepliTope™) and production of customized microarrays (PepStar™). In addition, we provide full assay and analysis service. Please inquire for our service offers.
- Immune monitoring of humoral responses
- Profiling of HIV specific samples or antibodies
- Detection of epitopes and epitope spreading
- Vaccine target identification
Catalog RepliTope™ Ultra Peptide Microarray
JPT’s HIV Ultra microarray displays overlapping peptide scans through HIV gag p17 and p24, tat, nef, env and the remaining immunogenic regions of the HIV proteome (6564 15mer peptides). It covers sequences from the most frequent clades (A, B, C, D, G, CRF1, CRF2) of HIV 1. We also offer our assay and analysis service using your samples with this high-content HIV peptide microarray.
> Catalog RepliTope™ Peptide Microarrays Product Page
Tailored PepStar™ Peptide Microarrays
You define content and layout, we provide economic and fast production in our regulated clean-room environment. We also offer our assay and analysis service using your samples with your tailored HIV peptide microarrays.
> Tailored PepStar™ Peptide Microarrays Product Page
In addition to high-content peptide microarrays, JPT offers the development of peptide based enzyme-linked immunosorbent assays (ELISA). This common analytical and highly sensitive immunological assay is well established for proteins but requires detailed experimental know-how for peptides. Peptide ELISA is offered as stand alone service for mapping of epitopes and definition of protein interaction sites or as validation assay to confirm results obtained with JPT’s peptide microarrays.
JPT’s Clinical Peptides product lines GxP and ISO Plus are produced in production environments that are regulated by an enhanced ISO 9001:2015 quality management system for the stringent product requirements of immunotherapy as well as vaccine and drug development. Depending on the specifics of the immunotherapy concept to be applied, the resulting products have been shown to be applicable in clinical applications.
"Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious Diseases"
Santos et al, Journal of Immunology Research (2019)
"T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral Therapy"
Thomas et al, PLoS Pathogen(2019)
"Envelope-Specific Epitope Recognition Patterns of HIV Vaccine-Induced IgG Antibodies are Linked to Immunogen Structure and Sequence"
Nadai et al, Front. Immunol (2019)
"Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs"
Bricault et al, Journal of Virology (2018)
"Cytomegalovirus-specific T-cells Are Associated with Immune Senescence, But Not With Systemic Inflammation, in People Living with HIV"
Ballegaard et al, Sci Rep. (2018)
"Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 Infection"
Kiniry et al, The Journal of Immunology (2018)
“The RV 144 HIV trial is considered as one of the first successful HIV vaccine trials. It has become clear that the V2 loop of gp120 is an important site for immunogenicity and protection from HIV infection. The use of JPT’s PepStarTM microarray technology has been very useful for the correlation of the clincial outcome with humoral immune responses. As have the cyclic peptides been from JPT to validate these findings!”
J. Currier, PhD., Walter Reed Army Institute, Rockville, Maryland, USA.
The Challenge of Antigen Sequence Diversity: Solutions with ULTRA‐Peptide Libraries
Reimer, Application Note (2015)
Developing Multi‐HIV Antigen Specific T Cells as a Component of a Cure Strategy
Gary et al., Application Note (2015)
Qualification and Use of Peptide Libraries for Clinical Trial Immunomonitoring
Cox et al., Application Note (2013)
A Modular Approach for Epitope Discovery and High-Resolution Profiling of Humoral Immune Responses
Pawlowski et al., Application Note (2013)
More application notes